From chromosomal alterations to target genes for therapy: integrating cytogenetic and functional genomic views of the breast cancer genome.
A vast number of recurrent chromosomal alterations have been implicated in cancer development and progression. However, most of the genes involved in recurrent chromosomal alterations in solid tumors remain unknown, despite the recent substantial progress in genomic research and availability of high-throughput technologies. For example, it is now possible to quickly identify large numbers of differentially expressed genes in cancer specimens using cDNA microarrays. Integration of this "functional genomic view" of the cancer genome with the "cytogenetic view" could lead to the identification of genes playing a critical role in cancer development and progression. In this review, we illustrate how the combination of three different microarray technologies, cDNA, CGH, and tissue microarrays, makes it possible to directly identify genes involved in chromosomal rearrangements in cell line model systems and then rapidly explore their significance as potential diagnostic and therapeutic targets in human primary breast cancer progression.
Monni
O
O
Cancer Genetics Branch, National Human Genome Research Institute, NIH, 49 Convent Drive, Bethesda, MD 20892, USA.
Hyman
E
E
Mousses
S
S
Barlund
M
M
Kallioniemi
A
A
Kallioniemi
O P
OP
D001943:Breast Neoplasms / Q000235:genetics* / Q000628:therapy*; D002869:Chromosome Aberrations; D003582:Cytogenetics; D018076:DNA, Complementary / Q000378:metabolism; D005821:Genetic Techniques; D016678:Genome; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis
D018076:DNA, Complementary